Skip to main content

Table 3 Results of univariate Cox analysis for time to PSA progression

From: Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials

 

JPN-201

JPN-202

 

Chemotherapy-naive

Chemotherapy-treated

 

HR

95 % CI

HR

95 % CI

Maximum % PSA decline

0.975

0.964–0.986

0.981

0.975–0.987

Time to PSA nadir (months)

0.818

0.741–0.903

0.153

0.081–0.291

Nadir PSA value (ng/mL)

1.012

1.002–1.022

1.001

0.999–1.002

% PSA decline at week 4

0.989

0.981–0.998

0.980

0.973–0.986

% PSA decline at week 12

0.981

0.974–0.989

0.998

0.984–0.992

PSA decline (≥30 %) at week 4

 Non-decline (reference)

 Decline

0.753

0.341–1.664

0.342

0.180–0.648

PSA response (≥30 %) at week 12

 Non-responder (reference)

 Responder

0.331

0.158–0.692

0.335

0.167–0.674

PSA response (≥50 %) at week 12

 Non-responder (reference)

 Responder

0.394

0.119–0.781

0.298

0.141–0.627

PSA response (≥90 %) at week 12

 Non-responder (reference)

 Responder

0.357

0.137–0.930

0.807

0.193–3.369

  1. CI confidence interval, HR hazard ratio, PSA prostate-specific antigen